Currently, it is being evaluated in various clinical trials for HER2-positive gastric cancer, colorectal cancer with HER2 mutations or overexpression, and NSCLC with HER2 alterations, reporting promising preliminary results. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.